Reply to Letter: factors affecting COVID-19 outcomes in patients with congenital heart diseaseGeneral Cardiology Published on 2021-01-072022-10-31 Journal: Cardiology in the Young [Category] Coronavirus, MERS, [키워드] affecting congenital heart coronavirus COVID-19 disease Factor outcome paediatric patients Patient Reply [DOI] 10.1017/S1047951120004941 PMC 바로가기 [Article Type] General Cardiology
Reply to: Memory box: possibilities to support grief in the intensive care unit during the COVID-19 pandemicAuthors' Response Published on 2021-01-012022-10-29 Journal: Revista Brasileira de Terapia Intensiva [Category] Coronavirus, MERS, SARS, [키워드] COVID-19 pandemic intensive care Reply Support [DOI] 10.5935/0103-507X.20210045 PMC 바로가기 [Article Type] Authors' Response
Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patientsWang et al.에 대한 답변: Tocilizumab 치료는 적시에 적절한 용량으로 적절한 환자에게 사용해야 합니다.Comment Published on 2020-12-082022-09-12 Journal: Proceedings of the National Academy of Sciences of [Category] MERS, SARS, 진단, [키워드] dose Patient Reply Treatment [DOI] 10.1073/pnas.2017204117 PMC 바로가기 [Article Type] Comment
Response to ‘No evidence of SARS-CoV-2 infection by polymerase chain reaction or serology in children with pseudo-chilblain’. Reply from the authors'가성 어린이의 중합효소 연쇄 반응 또는 혈청학에 의한 SARS-CoV-2 감염의 증거 없음'에 대한 응답. 저자의 답변Comment Published on 2020-12-012022-09-12 Journal: The British journal of dermatology [Category] MERS, SARS, 진단, [키워드] children Evidence polymerase chain Reply response SARS-COV-2 infection serology [DOI] 10.1111/bjd.19563 PMC 바로가기 [Article Type] Comment
Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely interventionYang et al.에 대한 답변: COVID-19 환자의 토실리주맙 치료는 질병 중증도 및 시기 적절한 개입에 대한 평가가 필요합니다.Comment Published on 2020-12-012022-09-12 Journal: Proceedings of the National Academy of Sciences of [Category] SARS, 진단, [키워드] COVID-19 patient Intervention Reply severity the disease Treatment [DOI] 10.1073/pnas.2011616117 PMC 바로가기 [Article Type] Comment
Reply to “Antiviral and anti-inflammatory properties of ivermectinand its potential use in Covid-19”"이버멕틴의 항바이러스 및 항염증 특성 및 Covid-19에서의 잠재적 사용"에 대한 답변Comment Published on 2020-12-012022-09-11 Journal: Monatsschr Kinderheilkd (1902) [Category] SARS, 치료제, [키워드] anti-inflammatory property Reply [DOI] 10.1016/j.arbr.2020.11.002 PMC 바로가기 [Article Type] Comment
Reply to “Antiviral and anti-inflammatory properties of ivermectinand its potential use in COVID-19”"이버멕틴의 항바이러스 및 항염증 특성 및 COVID-19에서의 잠재적 사용"에 대한 답변Comment Published on 2020-12-012022-09-11 Journal: Monatsschr Kinderheilkd (1902) [Category] SARS, 치료제, [키워드] anti-inflammatory property Reply [DOI] 10.1016/j.arbres.2020.09.004 PMC 바로가기 [Article Type] Comment
Reply to: “Vitamin D Insufficiency May Account for Almost Nine of Ten COVID-19 Deaths: Time to Act. Comment on: Vitamin D Deficiency and Outcome of COVID-19 Patients. Nutrients 2020, 12 , 2757”Reply Published on 2020-11-272022-10-31 Journal: Nutrients [Category] Coronavirus, SARS, [키워드] Act Comment COVID-19 insufficiency nutrient Reply time Vitamin D [DOI] 10.3390/nu12123643 PMC 바로가기 [Article Type] Reply
Authors’ Reply to: Errors in Tracing Coronavirus SARS-CoV-2 Transmission Using a Maximum Likelihood Tree. Comment on “A Snapshot of SARS-CoV-2 Genome Availability up to April 2020 and its Implications: Data Analysis”Letter to the Editor Published on 2020-11-112022-10-31 Journal: JMIR Public Health and Surveillance [Category] COVID-19, SARS, [키워드] cladogram Comment error Maximum likelihood Phylogeny Reply SARS-CoV-2 tracing tree [DOI] 10.2196/24661 PMC 바로가기 [Article Type] Letter to the Editor
Reply to Comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic”Correspondence Published on 2020-11-032022-10-28 Journal: British Journal of Cancer [Category] Coronavirus, MERS, SARS, [키워드] Comment Consensus COVID-19 Pancreatic cancer Reply Treatment [DOI] 10.1038/s41416-020-01133-8 PMC 바로가기 [Article Type] Correspondence